Molecular mechanisms of increased glucose production: Identifying potential therapeutic targets

Journal of Investigative Medicine

Volumn 52, Issue 6, 2004, Pages 389-393

  Proietto, Joseph ^a   Andrikopoulos, Sofianos ^a  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Endogenous glucose production; Gluconeogenesis; Glycogenolysis

Indexed keywords

11BETA HYDROXYDEHYDROGENASE 1 INHIBITOR; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR BLOCKING AGENT; BVT 3498; C ENHANCER BINDING PROTEIN BETA INHIBITOR; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT ACTIVITY MODULATOR; DICHLOROACETIC ACID; ENZYME INHIBITOR; FRUCTOSE BISPHOSPHATASE; GENE EXPRESSION MODULATOR; GLUCAGON; GLUCAGON RECEPTOR; GLUCAGON RECEPTOR ANTAGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUCOSE 6 PHOSPHATASE; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE KINASE 3; HORMONE; HORMONE RECEPTOR AFFECTING AGENT; LIVER X RECEPTOR; NUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA AGONIST; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOTRANSFERASE; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; HEART HYPERTROPHY; HUMAN; INSULIN TREATMENT; METABOLIC DISORDER; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RECEPTOR BLOCKING; THERAPEUTIC TARGET; THERAPY;

EID: 9244241518     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-06-33     Document Type: Conference Paper

References (29)

1. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment: and monitoring of metabolic control. Diabetes Care 2001;24:2023-9.
2. Stumvoll M, Meyer C, Mitrakou A, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997;40:749-57.
3. Petersen KF, Laurent D, Rothman DL, et al. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998;101:1203-9.
4. Boden G. Gluconeogenesis and glycogenolysis in health and diabetes. J Invest Med 2004;52:311-313.
5. Consoli A, Nurjhan N, Reilly JJ Jr, et al. Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Invest 1990;86:2038-45.
6. Puhakainen I, Koivisto VA, Yki-Jarvinen H. Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992;75:789-94.
7. Nurjhan N, Consoli A, Gerich J. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:169-75.
8. Veroni MC, Proietto J, Larkins RG. Evolution of insulin resistance in New Zealand obese mice. Diabetes 1991;40:1480-7.
9. Andrikopoulos S, Proietto J. The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1995;38:1389-96.
10. Andrikopoulos S, Rosella G, Gaskin E, et al. Impaired regulation of hepatic fructose-1,6-bisphosphatase in the New Zealand obese mouse model of NIDDM. Diabetes 1993;42:1731-6.
11. Andrikopoulos S, Rosella G, Kaczmarczyk SJ, et al. Impaired regulation of hepatic fructose-1,6-biphosphatase in the New Zealand obese mouse: an acquired defect. Metabolism 1996;45:622-6.
12. Song S, Andrikopoulos S, Filippis C, et al. Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. Am J Physiol Endocrinol Metab 2001;281:E275-82.
13. Kurukulasuriya R, Link JT, Madar DJ, et al. Prospects for pharmacologic inhibition of hepatic glucose production. Curr Med Chem 2003;10:99-121.
14. Martin WH, Hoover DJ, Armento SJ, et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci U S A 1998;95:1776-81.
15. Cline GW, Johnson K, Regittnig W, et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002;51:2903-10.
16. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-84.
17. Rosella G, Zajac JD, Baker L, et al. Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Mol Endocrinol 1995;9:1396-404.
18. Thorburn AW, Baldwin ME, Rosella G, et al. Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene. Diabetologia 1999;42:419-26.
19. Lamont BJ, Andrikopoulos S, Funkat A, et al. Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney. Diabetologia 2003;46:1338-47.
20. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991;40:1259-66.
21. Buhl ES, Jessen N, Schmitz O, et al. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 2001;50:12-7.
22. Herling AW, Burger H, Schubert G, et al. Alterations of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats. Eur J Pharmacol 1999;386:75-82.
23. Brand CL, Jorgensen PN, Svendsen I, Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996;45:1076-83.
24. McCormack JG, Westergaard N, Kristiansen M, et al. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 2001;7:1451-74.
25. Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem 1997;272:31475-81.
26. Yasuda N, Inoue T, Horizoe T, et al. Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. Eur J Pharmacol 2003;459:159-66.
27. Harada H, Asano O, Hoshino Y, et al. 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor. J Med Chem 2001;44:170-9.
28. Stacpoole PW, Moore GW, Kornhauser DM. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978;298:526-30.
29. Anderson RC, Balestra M, Bell PA, et al. Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. J Med Chem 1995;38:3448-50.